Want to see SOLV full AI Analyst Report?
SOLV Stock Chart & Stats
$70.48
-$0.47(-0.68%)
At close: 4:00 PM EST
$70.48
-$0.47(-0.68%)
Day’s Range― - ―
52-Week Range$62.38 - $88.20
Previous CloseN/A
Volume531.14K
Average Volume (3M)1.20M
Market Cap
$13.45B
Enterprise Value$17.43B
Total Cash (Recent Filing)$561.00M
Total Debt (Recent Filing)$5.08B
Price to Earnings (P/E)9.4
Beta0.69
Next Earnings
Aug 05, 2026EPS Estimate
1.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.21
Shares Outstanding173,174,710
10 Day Avg. Volume882,498
30 Day Avg. Volume1,201,928
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.73
Price to Sales (P/S)1.66
P/FCF Ratio-1.38K
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue2.11
Enterprise Value/Gross Profit3.93
Enterprise Value/Ebitda6.33
Forecast
1Y Price Target
$83.00Price Target Upside17.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)6.55
Revenue Forecast (FY)$8.19B
Bulls Say, Bears Say
Bulls Say
Strong Margins And Margin GuidanceSustained high gross margins and management's explicit operating margin target (21.0%–21.5%) indicate durable pricing power and favorable product mix across MedSurg, Dental and HIS. Combined with disciplined cost programs, this supports structural margin sustainability beyond transient cycles.
Diversified, Growing Segments (MedSurg, Dental, HIS)Broad, multi-product business mix with recurring software and RCM offerings reduces reliance on any single end market. HIS growth (autonomous coding, international expansion) and steady MedSurg/Dental organic gains provide multiple durable revenue levers and improve resilience to single-segment shocks.
Multi-year Cost Savings And Portfolio OptimizationA formal $500M multiyear savings program, active SKU rationalization and targeted M&A/portfolio moves are structural initiatives that lower the cost base, simplify operations and improve long-term cash conversion and margins rather than relying on one-off savings.
Bears Say
Weak Cash Conversion And Negative FCFThe persistent gap between reported profits and operating cash weakens financial flexibility. Negative free cash flow constrains capacity to de-lever, invest in growth or sustain buybacks without external funding, increasing sensitivity to working-capital and one-time separation timing effects.
Stagnant Or Declining Revenue TrendsFlat to declining top-line performance reduces operating leverage and forces reliance on cost cuts and asset sales to hit targets. Organic growth is modest and reporting volatility from M&A/divestitures masks demand trends, complicating medium-term revenue sustainability.
Tariff, ERP Phasing And Elevated Net DebtOngoing tariff exposure, ERP cutover phasing that shifts >$100M of orders and remaining separation costs drive persistent cash and quarter-to-quarter volatility. Elevated net debt (~$4.5B) limits flexibility to absorb these shocks and increases refinancing and liquidity risk if cash conversion doesn't improve.
Solventum Corporation News
SOLV FAQ
What was Solventum Corporation’s price range in the past 12 months?
Solventum Corporation lowest stock price was $62.38 and its highest was $88.20 in the past 12 months.
What is Solventum Corporation’s market cap?
Solventum Corporation’s market cap is $13.45B.
When is Solventum Corporation’s upcoming earnings report date?
Solventum Corporation’s upcoming earnings report date is Aug 05, 2026 which is in 12 days.
How were Solventum Corporation’s earnings last quarter?
Solventum Corporation released its earnings results on May 05, 2026. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.353 by $0.127.
Is Solventum Corporation overvalued?
According to Wall Street analysts Solventum Corporation’s price is currently Undervalued.
Does Solventum Corporation pay dividends?
Solventum Corporation does not currently pay dividends.
What is Solventum Corporation’s EPS estimate?
Solventum Corporation’s EPS estimate is 1.91.
How many shares outstanding does Solventum Corporation have?
Solventum Corporation has 173,174,710 shares outstanding.
What happened to Solventum Corporation’s price movement after its last earnings report?
Solventum Corporation reported an EPS of $1.48 in its last earnings report, beating expectations of $1.353. Following the earnings report the stock price went up 2.824%.
Which hedge fund is a major shareholder of Solventum Corporation?
Currently, no hedge funds are holding shares in SOLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Solventum Corporation Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$83.00 (17.76% Upside)
$83.00 (17.76% Upside)
Blogger Sentiment
Bullish
SOLV Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 301.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.81%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.96%
Trailing 12-Months
Company Description
Solventum Corporation
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.
SOLV Stock 12 Month Forecast
Average Price Target
$83.00
▲(17.76% Upside)
Technical Analysis
DaVita
―
Fresenius Medical Care
―
Encompass Health
―
Tenet Healthcare
―
Universal Health
―
Ownership Overview
14.99% Insiders
19.91% Mutual Funds
0.77% Other Institutional Investors
43.30% Public Companies and
Individual Investors